Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

This was the stock's second consecutive day of losses.

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

There was a mix-up regarding my appointment for blood testing this morning. I arrived on time for my appointment but the kiosk indicated no appointment scheduled. It was 10 minutes to 12 (office ...

Quest Diagnostics Inc.’s DGX investments in Advanced Diagnostics are paying off, aiming to deliver and scale innovative services that improve patient care and drive growth. The company focuses ...

“We are confident in Quest’s ability to grow at above-market rates in our core physician and hospital channels driven by increased market access, double-digit growth in advanced diagnostics ...

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned diagnostics provider posted adjusted earnings per share (EPS ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...